Understanding Perimenopause: What Happens to Progesterone, Estradiol, and Testosterone?
Perimenopause is a major hormonal transition that can affect a woman's sleep, mood, metabolism, menstrual cycle, sexual health, cognitive function, and overall quality of life. Yet many women are told their symptoms are simply part of aging, even when hormonal changes may be contributing significantly.
Understanding how progesterone, estradiol, and testosterone change during this transition can help women recognize symptoms, understand their treatment options, and have more informed conversations with their healthcare providers.
One important distinction: hormones do not all decline in a neat, predictable sequence. Progesterone often becomes less consistent as ovulation becomes irregular, estradiol can fluctuate dramatically before declining overall, and testosterone generally declines gradually with age rather than suddenly at menopause.
Perimenopause is the transition leading up to menopause. It can begin in the late 30s or early 40s, but the most common onset is in the 40s. The duration varies considerably: some women experience a relatively short transition, while others experience symptoms for several years.
Menopause itself is defined retrospectively as 12 consecutive months without a menstrual period, provided there is no other explanation.
According to the STRAW+10 reproductive-aging staging framework, menstrual-cycle changes are an important indicator of the transition. A single hormone test is often insufficient to determine the stage because hormone concentrations can change substantially from day to day. [1,2]
2. What actually happens to hormones during perimenopause?
Progesterone: often becomes inconsistent first
Progesterone is produced mainly by the corpus luteum after ovulation. As ovulation becomes less frequent or less reliable, progesterone production may become lower or absent during some cycles. This can happen while estrogen production is still substantial.
Estradiol: fluctuates before its sustained decline.
Estradiol can rise to high levels in some cycles, fall sharply in others, and fluctuate unpredictably. Eventually, as ovarian follicular activity declines, estradiol generally falls to persistently lower levels after menopause.
Testosterone: a gradual, variable change
Testosterone is produced by the ovaries and adrenal glands and through peripheral conversion of precursor hormones. Levels tend to decline across the reproductive years, but there is no universal, abrupt testosterone collapse at menopause. A woman's symptoms cannot be predicted reliably from a single testosterone measurement.
This pattern is supported by the STRAW+10 staging framework and endocrine reviews of the menopausal transition. [1,2]
Why estradiol can be high one month and low the next?
As the ovarian follicle pool diminishes, the brain increases follicle-stimulating hormone (FSH) signaling in an attempt to stimulate the ovaries. The remaining follicles may respond inconsistently.
Consequently, a woman may experience:
A cycle with high estradiol and breast tenderness.
A cycle with lower estradiol and hot flashes or sleep disruption.
Shorter menstrual cycles, followed by longer cycles or skipped periods.
Changes in mood, energy, headaches, or menstrual bleeding that vary from month to month.
This explains why a woman can have significant perimenopausal symptoms despite an estradiol blood result that falls within a typical premenopausal reference range. The number represents one moment, not the entire hormonal pattern. [1,2,3]
An important clinical distinction: progesterone may be low or absent in an anovulatory cycle, but it is not accurate to say that every woman's progesterone falls to nearly zero before estradiol begins declining. Nor does estradiol always remain high throughout perimenopause.
3. Symptoms associated with low and high progesterone
Progesterone is involved in menstrual-cycle regulation, preparation of the uterine lining for pregnancy, and signaling through receptors in the brain, including pathways related to the neuroactive metabolite allopregnanolone.
Unlike estradiol, progesterone is naturally very low during the first part of a normal menstrual cycle and rises after ovulation. Therefore, the timing of testing is essential.
Low or insufficient progesterone
Symptoms or findings that may be associated with inadequate progesterone production include:
Shortened or irregular cycles and changes in menstrual bleeding.
Difficulty conceiving when ovulation is absent or irregular.
Heavy or prolonged bleeding in some anovulatory cycles, particularly when estrogen stimulates the uterine lining without sufficient progesterone opposition.
Sleep or mood changes in some women, although these symptoms are nonspecific and do not establish progesterone deficiency.
Reduced luteal-phase progesterone exposure when ovulation is inconsistent.
Clinical relevance: low progesterone in an anovulatory cycle can reflect the underlying ovulatory change rather than an isolated hormone deficiency.
High progesterone or progesterone exposure
Progesterone concentrations are normally high after ovulation and during pregnancy. When levels are elevated because of supplementation, possible effects include:
Sleepiness, fatigue, or dizziness.
Breast tenderness or bloating.
Headache or changes in mood.
Occasionally, changes in bleeding patterns.
These effects depend on the formulation, dose, route, timing, and individual response. Natural post-ovulation progesterone is not inherently harmful, and a higher level does not automatically mean a woman has a hormonal imbalance.
The evidence does not support diagnosing a generalized condition called “progesterone deficiency” solely from symptoms such as anxiety, insomnia, or weight gain. In menstruating women, progesterone must be interpreted in relation to ovulation and cycle timing.
4. Symptoms associated with low and high estradiol
Estradiol is the most potent of the major naturally occurring estrogens during the reproductive years. It has important effects on the reproductive tract, brain, bones, and other tissues.
Low estradiol
Symptoms that may be associated with declining or persistently low estradiol include:
Hot flashes and night sweats.
Vaginal dryness, irritation, and pain during intercourse.
Urinary urgency, discomfort, and recurrent urinary tract infections associated with genitourinary changes.
Sleep disruption, particularly when hot flashes occur at night.
Changes in mood, concentration, or perceived mental sharpness.
Joint aches or changes in sexual comfort.
Accelerated bone loss after menopause.
Not every woman experiences every symptom, and many symptoms have causes beyond estradiol.
High estradiol or periods of estrogen predominance
When estradiol rises substantially during some perimenopausal cycles, or estrogen exposure is relatively high compared with progesterone, some women may experience:
Breast fullness or tenderness.
Bloating or fluid retention.
Headaches or menstrual migraines.
Heavier or prolonged menstrual bleeding.
Increased menstrual cramping.
Symptoms that coincide with particular parts of the cycle.
However, these symptoms do not reliably diagnose high estradiol. They can occur at normal hormone levels or with other conditions.
Persistent heavy bleeding or bleeding between periods needs evaluation. Prolonged exposure to estrogen without adequate progestogen protection can also promote endometrial hyperplasia in women with a uterus.
The North American Menopause Society's hormone therapy position statement identifies systemic hormone therapy as the most effective treatment for vasomotor symptoms and recognizes its role in treating genitourinary symptoms and preventing bone loss. [4]
What do people mean by “estrogen dominance”?
The term is often used to describe a relative imbalance between estrogen and progesterone. It is not a standardized diagnosis with one universally accepted blood-test threshold.
During perimenopause, a woman may have substantial estrogen exposure during a cycle in which ovulation does not occur and progesterone remains low. That can be clinically relevant, particularly when bleeding is heavy or prolonged. However, symptoms alone cannot establish that estrogen is too high, and an estrogen-to-progesterone ratio does not have one validated cutoff that diagnoses all cases.
The priority is to assess the menstrual pattern, symptoms, medications, pregnancy possibility when relevant, and the risk of endometrial disease rather than assume every symptom reflects estrogen excess.
5. What could adding hormones do for a woman experiencing symptoms?
Hormone therapy is not simply about making every hormone number reach an ideal range. The goal is to identify the symptoms or health concerns that may respond to treatment, choose the appropriate hormone and route, and balance the expected benefits against risks.
Progesterone: sleep, bleeding, and uterine protection
Potential Benefits
Oral micronized progesterone may improve sleep in some women, although the evidence is still limited.
A prescribed progestogen can regulate bleeding in selected women with irregular cycles.
Progesterone or another appropriate progestogen protects the uterine lining when systemic estrogen is used by a woman who has an intact uterus.
It may help manage some hormone-related symptoms, depending on the cause and treatment regimen.
A systematic review and meta-analysis by Nolan and colleagues examined micronized progesterone and sleep. Some studies found improvements in sleep outcomes, but the studies were relatively small and the evidence was not conclusive for all sleep measures. [5]
Important: progesterone is not a universal treatment for anxiety, insomnia, or every symptom attributed to perimenopause. Oral micronized progesterone can cause drowsiness and dizziness. It is also not contraception.
Estradiol: hot flashes, vaginal and urinary symptoms, and bone health
Potential Benefits
Reduces hot flashes and night sweats.
Can improve sleep when sleep disruption is driven by vasomotor symptoms.
Systemic treatment can help prevent bone loss and reduce fracture risk while treatment is used.
Improves vaginal and urinary symptoms when appropriately prescribed; low-dose vaginal estrogen is particularly useful for localized genitourinary symptoms.
May improve menopause-related quality of life.
The 2022 North American Menopause Society position statement concluded that hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause, and that it prevents bone loss and fractures. For many healthy symptomatic women younger than 60 or within 10 years of menopause, the benefit-risk balance is favorable when there are no contraindications. [4]
There are important differences between systemic and local estrogen. Low-dose vaginal estrogen can treat local symptoms with much less systemic exposure than most systemic regimens. Systemic estradiol may be appropriate for hot flashes, night sweats, and broader indications.
Uterine protection matters: women with an intact uterus generally need an adequate progestogen regimen alongside systemic estrogen to reduce the risk of endometrial hyperplasia and cancer. Estrogen alone is generally used for systemic menopausal therapy in women who have had a hysterectomy.
Testosterone: sexual desire and function
Potential Benefits
May improve sexual desire in postmenopausal women diagnosed with hypoactive sexual desire disorder (HSDD).
Can improve sexual arousal, pleasure, orgasmic function, and sexual responsiveness in appropriately selected women.
May reduce sexual distress associated with persistent low desire.
Evidence does not currently establish that testosterone therapy reliably improves energy, cognition, mood, muscle mass, or general well-being in all women with low measured testosterone.
The 2019 Global Consensus Position Statement on Testosterone Therapy for Women reviewed randomized controlled trials and concluded that the evidence-based indication was treatment of HSDD in postmenopausal women following a thorough clinical assessment. The average benefit was approximately one additional satisfying sexual event per month over placebo, with improvements in other aspects of sexual function. Long-term safety remains uncertain. [6]
Testosterone is not automatically indicated simply because a woman's laboratory result is below a reference range. If treatment is considered, clinicians generally aim to maintain concentrations within the physiological premenopausal female range and monitor for acne, excess facial hair, scalp hair loss, voice changes, and other adverse effects. There is no FDA-approved testosterone product specifically for women in the United States.
7. How should hormone therapy be approached during perimenopause?
A woman does not need to wait until her periods stop completely before seeking treatment for troublesome symptoms. However, the appropriate approach depends on her age, menstrual status, medical history, contraceptive needs, and whether the primary problem is irregular bleeding, hot flashes, sleep disruption, vaginal symptoms, or low sexual desire.
A useful clinical framework is:
Establish the symptom pattern. Record menstrual timing, bleeding volume, hot flashes, sleep quality, mood changes, sexual function, and symptom timing.
Rule out other causes. Thyroid dysfunction, anemia, pregnancy, medication effects, sleep disorders, and other conditions can resemble perimenopausal symptoms.
Choose treatment for the clinical indication. Hormonal contraception may be preferable for some women who need contraception and cycle control. Menopausal hormone therapy may be appropriate for others, but it is not contraception.
Choose the appropriate route and formulation. Transdermal estradiol, oral estradiol, oral micronized progesterone, other progestogens, and local vaginal treatments have different uses and risk profiles.
Reassess response and safety. Monitor symptoms, bleeding, side effects, and relevant clinical risks rather than escalating doses solely to reach a particular laboratory number.
Routine hormone testing is generally unnecessary to diagnose typical perimenopause in women over 45 because results fluctuate substantially. Testing can be useful when the presentation is atypical, menopause occurs early, or another endocrine condition is suspected. [3,7]
Women with a history of breast or endometrial cancer, unexplained vaginal bleeding, previous blood clots, stroke, significant liver disease, or other relevant conditions need individualized assessment before hormone treatment.
Persistent heavy bleeding should not automatically be attributed to hormonal fluctuations. Bleeding after menopause always warrants prompt medical evaluation.
8. Research papers and clinical references
These are useful primary references for a patient education article, wellness presentation, or further professional reading.
1. Harlow et al. (2012). Executive Summary of STRAW+10.
Menopause, 19(4), 387–395.
Establishes the accepted stages of reproductive aging and describes the menstrual and endocrine changes used to characterize the menopausal transition.
2. Prior (2014). The perimenopausal woman: Endocrinology and management.
The Journal of Steroid Biochemistry and Molecular Biology, 142, 121–131.
Reviews ovarian aging, follicular development, and the hormonal changes underlying perimenopause.
3. American College of Obstetricians and Gynecologists. Hormone testing during perimenopause.
Explains why symptoms, age, and menstrual changes are often more informative than an isolated hormone result.
4. The North American Menopause Society (2022). The 2022 hormone therapy position statement.
Menopause, 29(7), 767–794.
Comprehensive evidence review of the benefits, risks, indications, and individualized use of menopausal hormone therapy.
5. Nolan et al. (2021). Efficacy of micronized progesterone for sleep: A systematic review and meta-analysis.
The Journal of Clinical Endocrinology & Metabolism, 106(4), e942–e951.
Evaluates clinical evidence for progesterone's effects on sleep.
6. Davis et al. (2019). Global Consensus Position Statement on the Use of Testosterone Therapy for Women.
The Journal of Clinical Endocrinology & Metabolism, 104(10), 4660–4666.
Summarizes evidence for testosterone treatment, sexual-function benefits, safety concerns, and limitations of the evidence.
7. American College of Obstetricians and Gynecologists. Menopause and perimenopause clinical resources.
Provides patient-centered guidance on symptoms, hormone evaluation, and management.
Explore ACOG's menopause resources
The bottom line
Perimenopause is not simply a period when all hormones decline together. Progesterone production may become inconsistent as ovulation becomes irregular; estradiol may fluctuate dramatically before its sustained postmenopausal decline; and testosterone generally changes more gradually.
Hormone therapy can be very beneficial when selected for an appropriate indication, but the best treatment is not necessarily to replace all three hormones. It is to understand the woman's symptoms, establish what is driving them, choose an evidence-based treatment, and monitor the results.
The goal is better health and quality of life—not simply higher hormone numbers.
Do you have actual memory loss, or is it just natural "senior moments? Everyone 60 and older should perform this test to have the best chance of maintaining full brain and memory function with aging.
The CNS (central nervous system) vital signs test is the best and lowest-cost test you can take. You can do it at home on your computer or tablet. It takes about 30 minutes and provides a detailed, scientifically validated report. Importantly, this can catch brain/memory problems before they impact your life and when the process is MOST REVERSIBLE. Here are images showing how this test can determine if you are actually losing brain volume prematurely, and to what extent.
How does this test compare to standard-of-care testing, specifically an MRI? Published studies show that if you get an MRI because of suspected cognitive impairment, the person already has about a 15% loss in their brain memory center, the Hippocampus. Our experience indicates that people with this much brain loss seldom see improvement, even with the most effective treatments available today.
Updates
Get low- and no-cost health tips and root-cause solutions.
FrugalDoc
Affordable Health & Wellness
© 2025 FrugalDoc Health & Wellness. All rights reserved.